Shareholder Update Q3 2018 Highlights: Venous leg ulcer Phase 2 trial on track:  top-line results mid-NovemberDiabetic foot ulcer pilot clinical study: in development with key US researchersOcular wounds: international patent...

Phase 2 Clinical Trial for Venous Leg Ulcers Nears Completion BRISBANE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is...

Factor Therapeutics Announces Commencement of Phase II Trial of a Novel Topical Biologic for the Treatment of Chronic Wounds BRISBANE, Australia, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX:FTT) is pleased to announce that it has enrolled the first patient for its US multi-centre Phase II trial of...